Japan· JP-2399006C1190
トリメブチンマレイン酸塩
A trimebutine product containing トリメブチンマレイン酸塩, registered in Japan by 鶴原製薬, on the national reimbursement list. The same ATC class is registered in 6 of our 19 countries.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
Where it is registered
Trimebutine is registered in 6 of 19 countries.
Countries holding a registration under ATC A03AA05 (trimebutine), each read from that country’s own register.
- This record: Japan, from MHLW / PMDA (Japan)
- 4 of them publish a price we can compare per daily dose
Trimebutine · ATC A03AA05
6 / 19 countries
- Canada
- Franceprice
- Japan
- Norwayprice
- Polandprice
- Switzerlandprice
Price per daily dose
What a daily dose of trimebutine costs, country by country.
Normalised to the WHO defined daily dose (0.6 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Trimebutine · price per daily dose (0.6 g)
USD · FX 28 Sept 2026
- FR France$0.54
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- トリメブチンマレイン酸塩
- Manufacturer
- 鶴原製薬
- Country
- Japan (JP)
- ATC code
- A03AA05
- ATC class
- Trimebutine
- Defined daily dose
- 0.6 g, O
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under A03AA05
Trimebutine, as other registers publish it.
- CanadaAPO-TRIMEBUTINEAPOTEX INC
- CanadaAPO-TRIMEBUTINEAPOTEX INC
- PolandDebretinZakłady Farmaceutyczne POLPHARMA S.A.
- PolandDebretin ForteZakłady Farmaceutyczne POLPHARMA S.A.
- PolandDebretin NeoZakłady Farmaceutyczne POLPHARMA S.A.
- PolandDebridatInPharm Sp. z o.o.
- PolandDebridatForfarm Sp. z o.o.
- PolandDebridatPfizer Europe MA EEIG
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/dc319848-34ca-4ffe-ba06-7c930525c1af GET /v1/drugs/dc319848-34ca-4ffe-ba06-7c930525c1af?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "２０％１ｇ",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "2399006C1190",
"category": "内用薬",
"price_yen": 13.7,
"generic_name": "トリメブチンマレイン酸塩",
"product_name_jp": null,
"therapeutic_class": "2399",
"transitional_expiry": null
}See everything about trimebutine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.